Cyclacel Pharma (CYCC) Reports Q4 Loss of $0.62

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/30/2026

1. INTC
2. AMZN
3. COIN
4. PINS
5. RDDT
6. FSLR
7. SYK
8. DASH
9. SBUX
10. MA

Go back to Cyclacel Pharma (CYCC) Reports Q4 Loss of $0.62

Cyclacel Pharma (CYCC) Says Publication Identifies Cyclin E as Key Resistance Pathway to Breast Cancer Treated by CDK4/6 Inhibitors

March 25, 2019 7:03 AM EDT

Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) (Nasdaq: CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing innovative medicines based on cancer cell biology, highlighted a paper from independent investigators titled Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone ReceptorPositive Metastatic Breast Cancer published in the most recent edition of the Journal of Clinical Oncology (Turner N et al, 2019... More